Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Top Drugs 1 > Antibiotics 1 > Flashcards

Antibiotics 1 Flashcards

1
Q

Ciprofloxacin (otic)

A

Cipro HC, Cipro XR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Ciprofloxacin (oral)

A

Cipro, Cipro Xr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Gatifloxacin (ophthalmic)

A

Zymar, Zymaxid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Levofloxacin

A

Levaquin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Moxifloxacin (ophthlamic)

A

Vigamox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Moxifloxacin (oral)

A

Avelox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Nitrofurantoin

A

Macrodantin, Macrobid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Sulfamethoxazole/Trimethoprim (SMZ/TMP)

A

Bactrim, Septra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mupirocin

A

Bactroban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Therapeutic Class - Ciprofloxacin (otic)

A

Fluoroquinolone antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Therapeutic Class - Ciprofloxacin (oral)

A

Fluoroquinolone antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Therapeutic Class - Gatifloxacin (ophthalmic)

A

Fluoroquinolone antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Therapeutic Class - Levofloxacin

A

Fluoroquinolone antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Therapeutic Class - Moxifloxacin (ophthalmic)

A

Fluoroquinolone antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Therapeutic Class - Moxifloxacin (oral)

A

Fluoroquinolone antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Therapeutic Class - Nitrofurantoin

A

Nitrofuran antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Therapeutic Class - SMZ/TMP

A

Sulfonamide antibiotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Therapeutic Class - Mupirocin

A

Topical antibacterial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dosage Forms - Ciprofloxacin

A

IR Tablet: 100, 250, 500, 750 mg

ER Tablet: 500, 1000 mg

Oral Suspension: 250 mg/5 mL, 500 mg/5 mL

Otic Solution: 0.2%

Otic Suspension: 6 %

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Dosage Forms - Gatifloxacin

A

Ophthalmic Solution: 0.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Dosage Forms - Levofloxacin

A

IR Tablet: 250, 500, 750 mg

Oral Solution: 25 mg/mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Dosage Forms - Moxifloxacin

A

IR Tablet: 400 mg

Ophthalmic Solution: 0.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Dosage Forms - Nitrofurantoin

A

IR Capsule: 25, 50, 100 mg

Oral Suspension: 25 mg/5 mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Dosage Forms - SMZ/TMP

A 
IR Tablet: 400 mg/80 mg (SS = Single Strength), 800 mg/160 mg (DS = Double Strength)
Oral Suspension (per 5 mL): 200 mg/40 mg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Dosage Forms - Mupirocin

A

ALL 2%
Topical Ointment
Topical Cream
Nasal Ointment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

MOA - Ciprofloxacin

A

Inhibits bacteria DNA gyrase, an enzyme responsible for the unwinding of DNA for transcription and subsequent supercoiling of DNA for packaging into chromosomal subunits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Activity - Ciprofloxacin

A

Broad-spectrum

Highly active against aerobic, Gram (-) bacilli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

FDA-Approved Indications - Ciprofloxacin (otic)

A
  1. Otitis externa, acute (adults and children >1 year of age): 0.25 mL (entire single-use container) into affected ear(s) BID (approximately q12h) x 7 days
  2. Otitis media with effusion: 0.1 mL (6 mg) once intratympanically to each affected ear following suctioning of middle ear effusion during tympanostomy tube placement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

FDA-Approved Indications - Ciprofloxacin (oral)

A
  1. Anthrax, post-exposure prophylaxis
    Adults - 500 mg q12h x at least 60 days
    Children - 15 mg/kg BID x at least 60 days, max 500 mg/dose
  2. Bacterial prostatitis, chronic: 500 mg q12h x 28 days
  3. Bronchitis, lower respiratory tract infection, infection of bone, skin, or soft tissue, sinusitis: 500-750 mg q12h x 7-14 days
  4. UTI: 250-500 mg q12h x 3 days (IR); 500 mg q24h x 3 days (ER)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Off-Label Uses - Ciprofloxacin (oral)

A
  1. Traveler’s diarrhea: 750 mg as a single dose (mild); 500 mg BID x 3 days (sever)
  2. Diabetic foot infection: 500 mg q12h (750 mg q12h if P. aeruginosa is suspected), duration dependent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

MOA - Gatifloxacin

A

Inhibits bacterial DNA gyrase and topoisomerase IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Activity - Gatifloxacin

A

Broad-spectrum
Highly active against aerobic, gram-negative bacilli, especially Enterobacteriaceae

Has poor activity against streptococci and anaerobes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

FDA-Approved Indications - Gatifloxacin (ophthalmic)

A
  1. Bacterial conjunctivitis (adults and children > 1 year): 0.5 % ophthalmic solution - 1 drop into affected eye(s) q2h while awake on day 1 (MAX 8 doses/day), then QID while awake for 6 more days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

MOA - Levofloxacin

A

Inhibits bacterial DNA gyrase, an enzyme responsible for the unwinding of DNA for transcription and subsequent supercoiling of DNA for packing into chromosomal subunits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Activity - Levofloxacin

A

Broad-spectrum

Highly active against aerobic, gram-negative bacilli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

FDA-Approved Indications - Levofloxacin

A
  1. Bacterial prostatitis, chronic: 500 mg QD x 28 days
  2. Bacterial sinusitis, acute: 750 mg QD x 5 days
  3. Bronchitis, chronic, acute bacterial exacerbation: 500 mg QD x 7 days
  4. Community-acquired pneumonia: 500 mg QD x 7-14 days, or 750 mg QD x 5 days
  5. Infection of skin and/or subcutaneous tissue (uncomplicated): 500 mg QD x 7-14 days
  6. Pyelonephritis, acute: 250 mg QD x 10 days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Off-Label Uses - Levofloxacin

A
  1. Chlamydial inflection: 500 mg QD x 7 days

2. Traveler’s diarrhea: 500 mg QD x 1-3 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

MOA - Moxifloxacin

A

Inhibits bacterial topoisomerase II and IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Activity - Moxifloxacin

A

Broad-spectrum
Anaerobes
Effective for respiratory tract infections caused by S. pneumoniae, H. influenzae, and others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

FDA-Approved Indications - Moxifloxacin (ophthalmic)

A
  1. Bacterial conjunctivitis (adults and children >4 months of age): 1 drop into affected eye(s) BID (Moxeza) or TID (Vigamox) x 7 days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

FDA-Approved Indications - Moxifloxacin (oral)

A
  1. Acute bacterial exacerbation of chronic bronchitis: 400 mg QD x 5 days
  2. Bacterial sinusitis, acute: 400 mg QD x 10 days
  3. Community-acquired pneumonia: 400 mg QD x 7-14
  4. Infection of skin and/or subcutaneous tissue: 400 mg QD x 7-21 days
  5. Complicated intra-abdominal infections: 400 mg QD x 5-14 days
42
Q

Off-Label Uses - Moxifloxacin (oral)

A
  1. Tuberculosis: 400 mg QD x 6 months
43
Q

MOA - Nitrofurantoin

A

Synthetic nitrofuran inactivates bacterial ribosomes and is bactericidal in urine at therapeutic doses

44
Q

Activity - Nitrofurantoin

A

Active against most bacteria that cause UTIs except nearly all strains of Pseudomonas are resistant

45
Q

FDA-Approved Indications - Nitrofurantoin

A
  1. UTI treatment (adults and children >12 years of age): Macrobid 100 mg BID x 5-7 days; Furadantin, Macrodantin 50-100 mg q6h x 5-7 days
  2. UTI treatment (children >1 month of age): 5-7 mg/kg/day in divided doses q6h x 7 days (max 400 mg/day)
  3. UTI prophylaxis (adults): 50-100 mg QHS
  4. UTI prophylaxis (children > 1 month of age): 1 mg/kg/day in divided doses every 12-24 hours (max dose 100 mg/day)
46
Q

Off-Label Uses - Nitrofurantoin

A
  1. Asymptomatic bacteriuria in pregnancy: 100 mg BID x 4-7
47
Q

MOA - SMZ/TMP

A

SMZ competitively inhibits the synthesis of dihydropteroic acid (an inactive folic acid precursor) in microorganisms. TMP inhibits the enzymatic reduction of dihydrofolic acid to tetrahydrofolic acid. The combination is active against many bacteria and P. carinii. SMZ/TMP has in vitro activity against MRSA, but clinical success has been variable and unpredictable

48
Q

FDA-Approved Indications - SMZ/TMP

A
  1. Acute infective exacerbation of COPD: 800 mg SMZ and 160 mg TMP q12h x 3-7 days
  2. HIV infection, Pneumocystis pneumonia: 1600 mg SMZ and 320 mg TMP BID x 21 days
  3. HIV infection, Pneumocystis pneumonia, prophylaxis (adults): 800 mg SMZ and 160 mg TMP QD
  4. HIV infection, Pneumocystis pneumonia, prophylaxis (children > 1 month of age): 750 mg/m^2/day SMZ and 150 mg/m^2/day TMP in 2 divided doses 3 times/week on consecutive days
  5. Traveler’s diarrhea: 800 mg SMZ/160 mg TMP BID x 5 days
  6. UTI (adult): 800/160 BID x 10-14 days
  7. UTI (children > 2 months of age): 8 mg/kg TMP component/day BID x 10 days
49
Q

Off-Label Uses - SMZ/TMP

A
  1. Sinusitis: 800 mg/160 mg BID x 10-14 days

2. Prostatitis: 800 mg/160 mg BID x 4-6 weeks

50
Q

MOA - Mupirocin

A

Inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Because of this unique mechanism, mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial agents

51
Q

FDA-Approved Indications - Mupirocin

A
  1. Impetigo: apply topically TID x 3-5 days, reevaluate if no response
  2. Secondary skin infections: apply topically TID x 10 days, reevaluate if no response in 3-5 days
  3. Eradication of nasal colonization of MRSA during institutional outbreaks: apply 1/2 of single use tube to each nostril BID x 5 days
52
Q

Off-Label Uses - Mupirocin

A
  1. Surgical prophylaxis in MRSA carriers: apply 1/2 of single tube to each nostril BID x 5 days
53
Q

Kinetics - Ciprofloxacin (oral)

A

Absorption: F = 50-80%, minor food effect
Distribution: widespread (bile, CSF, gyn tissue, liver, lung, prostate, peritoneum, synovial fluid, sputum, etc)
Metabolism: not metabolized; P-gp substrate, strong inhibitor of CYP1A2
Elimination: renal 30-57%; T1/2 = 3-6 hours
Hepatic Dose Adjustment: none
Renal Dose Adjustment: CrCl 30-50 mL/min = 250-500 mg q12; CrCl 5-29 mL/min = 250-500 mg q18h

54
Q

Kinetics - Levofloxacin

A

Absorption: F = 99%, no food effect, take without regard to meals
Distribution: widespread (bile, blister, CSF, gyn tissues, lung, prostate, synovial fluid, sputum, tonsils)
Elimination: renal 87%; T1/2 = 6-8 hours
Hepatic Dose Adjustment: none
Renal Dose Adjustment: CrCl 20-50 mL/min = reduce dose by 50%; CrCl 5-19 mL/min = extend dosing interval to q48h

55
Q

Kinetics - Moxifloxacin (oral)

A

Absorption: F = 90%, no food effect, take without regard to meal
Distribution: Vd = 1.7-2.7 L/kg; abdominal tissue, bronchial mucosa, CSF, sinus, sputum; 30-50% protein binding
Metabolism: 52% hepatic via glucuronide and sulfate conjugation
Elimination: renal 20%; T1/2 of 12 h
Hepatic and Renal Dose Adjustment: none

56
Q

Kinetics - Nitrofurantoin

A

Absorption: F = 94%, food increases absorption
Distribution: 60-90% protein bound
Metabolism: in all tissues to inactive metabolite
Elimination: renal 20-25%; T1/2 = 1 hour
Hepatic Dose Adjustment: none
Renal Dose Adjustment: contraindicated if CrCl <60 mL/min

57
Q

Kinetics - SMZ/TMP

A

Absorption: F = 90%, no effect of food on absorption
Distribution: CSF, middle ear fluid, sputum, and vaginal fluid
Metabolism: hepatic >90%, TMP is CYP2C9 and CYP3A4/5 substrate; TMP is moderate inhibitor of CYP2C8 and CYP2C9
Elimination:
SMZ - renal 10-30%; T1/2 = 8-11 hours
TMP - renal 50-75%; T1/2 = 6-17 hours
Hepatic Dose Adjustment: none
Renal Dost Adjustment: CrCl 15-30 mL/min = reduce dose by 50%; CrCl <15 mL/min = avoid, or reduce by 50% and increase interval to 24 hour

58
Q

Drug Interactions - SMZ/TMP

A
  1. CYP3A4 and CYP3A5 inducers/inhibitors
  2. CYP2C8 and CYP2C9 substrates
  3. Agents that prolong QTc interval/antiarrhythmics - increased risk for arrhythmia (avoid use when possible)
  4. Methotrexate - synergistic antifolate effects (avoid use or monitor closely)
59
Q

Drug Interactions - Nitrofurantoin

A
  1. Fluconazole - increased risk for hepatic and pulmonary toxicity, mechanism unknown (avoid use or monitor closely)
60
Q

Drug Interactions - Oral Fluoroquinolones

A
  1. Di- and trivalent cations (Ca++, etc.), iron, sevelamer = decreased absorption by chelation (take 2 hour before or 6h after)
  2. Antidiabetic agents = hypo-and hyperglycemia, mechanism unknown (monitor closely)
  3. Corticosteroids = increased risk for tendon rupture (avoid concomitant use when possible)
  4. Warfarin - increased bleed risk (monitor INR closely)
  5. Agents that prolong QTc interval/antiarrhythmics - increased risk for arrhythmia (avoid use)
  6. Ciprofloxacin interacts with P-gp inducers/inhibitors
61
Q

Ciprofloxacin in Pregnancy/Lactation

A

Pregnancy: category C
2.
Lactation: weigh risks and benefits

62
Q

Gatifloxacin in Pregnancy/Lactation

A

Pregnancy: category C
Lactation: weigh risks and benefits

63
Q

Levofloxacin in Pregnancy/Lactation

A

Pregnancy: category C
Lactation: avoid

64
Q

Moxifloxacin in Pregnancy/Lactation

A

Pregnancy: category C
Lactation: avoid

65
Q

Nitrofurantoin in Pregnancy/Lactation

A

Pregnancy: category B
Lactation: usually safe

66
Q

SMZ/TMP in Pregnancy/Lactation

A

Pregnancy: avoid in pregnancy due to risk for malformations
Lactation: weigh risks vs. benefits

67
Q

Mupirocin in Pregnancy/Lactation

A

Pregnancy: category B
Lactation: weigh risks vs. benefits

68
Q

Black Box Warning - Ciprofloxacin

A

May exacerbate muscle weakness in patients with myasthenia gravis, tendon inflammation and rupture, peripheral neuropathy, CNS effects, cardiac dermatologic and hypersensitivity reactions, aortic dissection and rupture, hypoglycemia, mental health adverse effects

69
Q

Black Box Warning - Levofloxacin

A

May exacerbate muscle weakness in patients with myasthenia gravis, tendon inflammation and rupture, peripheral neuropathy, CNS effects, cardiac, dermatologic and hypersensitivity reactions, aortic dissection and rupture

70
Q

Black Box Warning - Moxifloxacin

A

May exacerbate muscle weakness in patients with myasthenia gravis, tendon inflammation and rupture, peripheral neuropathy, aortic dissection and rupture, hypoglycemia, delirium (oral only)

71
Q

Contraindications - Ciprofloxacin

A

Concomitant tizanidine with oral ciprofloxacin, hypersensitivity to any fluoroquinolone

72
Q

Contraindications - Gatifloxacin

A

Hypersensitivity to any fluoroquinolone

73
Q

Contraindications - Levofloxacin

A

Hypersensitivity to any fluoroquinolone

74
Q

Contraindications - Moxifloxacin

A

Hypersensitivity to any fluoroquinolone

75
Q

Contraindications - Nitrofurantoin

A

Hypersensitivity to nitrofurantoin, use in neonates or pregnant patients at term (38-42 wk) due to risk of hemolytic anemia, anuria or oliguria

76
Q

Contraindications - SMZ/TMP

A

Hypersensitivity to sulfonamides, children <2 mo, pregnant patients at term, megaloblastic anemia due to folate deficiency, history of drug-induced thrombocytopenia with use of sulfonamides or trimethoprim, marked hepatic damage or severe renal disease, concomitant administration with dofetilide

77
Q

Contraindications - Mupirocin

A

Hypersensitivity

78
Q

Beers Criteria - Nitrofurantoin

A

Avoid in renal dysfunction, avoid long-term use

79
Q

Adverse Effects - Ciprofloxacin (oral)

A

Common: tooth discoloration in infants, musculoskeletal signs and symptoms

Less common: N/V/D, rash, myalgia, arthralgia, tendonitis, headache, dizziness

Rare but serious: SJS, renal failure, anemia, neutropenia, thrombocytopenia, seizure, cardiac effects, liver failure, myasthenia gravis, tendon rupture, renal failure psychosis, QTc prolongation, peripheral neuropathy, CNS effects, severe cardiac, dermatologic, and hypersensitivity reactions

80
Q

Adverse Effects - Ciprofloxacin (otic)

A

Common: application site pain/itching

Less common: fungal ear superinfection

Rare but serious: hypersensitivity reaction

81
Q

Adverse Effects - Gatifloxacin

A

Common: none

Less common: Conjunctivitis, dry eyes, eye pain, subconjunctival hemorrhage, tearing and burning of the eyes, decreased visual acuity

Rare but serious: conjunctival hemorrhage

82
Q

Adverse Effects - Levofloxacin

A

Common: photosensitivity

Less common: N/V, rash, myalgia, arthralgia, tendonitis, headache

Rare but serious: Stevens-Johnson syndrome, renal failure, severe hypersensitivity, anemia, neutropenia, thrombocytopenia, seizure, cardiac arrest, cardiac arrhythmias, liver failure, tendon rupture, psychosis, glucose abnormalities,C. difficilecolitis, peripheral neuropathy, CNS effects, severe cardiac, dermatologic and hypersensitivity reactions

83
Q

Adverse Effects - Moxifloxacin (oral)

A

Common: none known

Less common: N/D, dizziness, headache

Rare but serious: Stevens-Johnson syndrome, renal failure, severe hypersensitivity, anemia, neutropenia, thrombocytopenia, seizure, cardiac arrhythmias, liver failure, tendon rupture, psychosis, exacerbation of myasthenia gravis, peripheral neuropathy, CNS effects, severe cardiac, dermatologic and hypersensitivity reactions

84
Q

Adverse Effects - Moxifloxacin (ophthalmic)

A

Common: none known

Less common: Conjunctivitis, dry eyes, eye pain, subconjunctival hemorrhage, tearing and burning of the eyes, decreased visual acuity

Rare but serious: fungal or bacterial ocular superinfection

85
Q

Adverse Effects - Nitrofurantoin

A

Common: discoloration of urine

Less common: D/N, headache, superinfection

Rare but serious: Severe hypersensitivity, hepatic failure, hemolytic anemia, interstitial lung disease

86
Q

Adverse Effects - SMZ/TMP

A

Common: D/N

Less common: skin rash, urticaria

Rare but serious: Severe hypersensitivity, renal failure, hepatic failure, pancytopenia, arrhythmias, Stevens-Johnson syndrome, hyperkalemia, hypoglycemia, hemolytic anemia

87
Q

Adverse Effects - Mupirocin

A

Common: none known

Less common: headache, pruritis, burning at site of application, stinging sensation, rhinitis

Rare but serious: C. difficile diarrhea

88
Q

Drug Monitoring - Ciprofloxacin

A

Efficacy: resolution of signs and symptoms of infection

Toxicity (systemic): renal function, baseline SCr

Toxicity (otic): secondary fungal infection, topical reactions

89
Q

Drug Monitoring - Gatifloxacin

A

Efficacy: resolution of signs and symptoms of infection

Toxicity: topical reactions

90
Q

Drug Monitoring - Levofloxacin

A

Efficacy: resolution of signs and symptoms of infection

Toxicity: renal function, baseline SCr

91
Q

Drug Monitoring - Moxifloxacin

A

Efficacy: resultion of signs and symptoms of infection

Toxicity (systemic): renal function, baseline SCr

Toxicity (otic): topical reactions

92
Q

Drug Monitoring - Nitrofurantoin

A

Efficacy: resolution of clinical signs and symptoms within 2-3 days

Toxicity: Severe diarrhea, yellowing of skin or eye, unusual bruising or bleeding, blistering skin rash, or shortness of breath. Signs of pulmonary reaction, numbness or tingling of extremities. With long-term use, CBC, LFTs, SCr.

93
Q

Drug Monitoring - SMZ/TMP

A

Efficacy: resolution and improvement of clinical signs of infection within 2-3 days

Toxicity: monitor renal function (SCr), potassium in those with concurrent ACEIs. Monitor FBG with concurrent sulfonylureas, insulin. CBC monthly if using for PCP prophylaxis.

94
Q

Drug Monitoring - Mupirocin

A

Efficacy: resolution of clinical signs of infection within 3-5 days, eradication of nasal colonization

Toxicity: seek medical attention if local adverse effects are severe

95
Q

Counseling and Pearls - General Fluoroquinolones (oral)

A

Counseling:

  1. Seek medical attention immediately for any s/s of serious adverse effects, such as blistering skin rash or extreme fatigue, unusual bruising or bleeding, shortness of breath or chest pain, tendon pain, muscle weakness, a “pins and needles” tingling or pricking sensation, numbness in the arms or legs, confusion or hallucinations.
  2. May take with or without food, but do not take with dairy products no any other food containing high calcium
  3. Separate from antacids, vitamins/minerals, sucralfate, or other chelating agents by 2hrs before or 6hrs after
  4. If tendon pain occurs, stop use and seek medical attention
  5. Shake ciprofloxacin oral suspension well before use
  6. Ciprofloxacin oral suspension may be stored at room temperature

Pearl

  1. Not approved for use in children <18 yrs (except cipro for anthrax or complicated UTI)
  2. Increased risk of tendon rupture in patients >60 y of age
  3. Due to risk of adverse reactions and availability of alternatives, patients with common infections (acute bacterial sinusitis, acute uncomplicated cystitis, etc) should not receive quinolone therapy
  4. Medication guide required at dispensing
96
Q

Counseling and Pearls - General Fluoroquinolones (otic, ophthalmic)

A

Counseling

  1. May warm solution in hands for 1 minute prior to administration
  2. Complete full course of therapy even if symptoms improve
  3. Otic: administer with affected ear upward, maintain position for at least 1 minute after instillation
  4. Ophthalmic: Wash hands with soap and water before/after use. Lie down or tilt head back. With index finger, pull down the lower lid of eye to form a pocket. Hold the dropper close to eye, but not touching, with the other hand. Drop the correct number of drops into the pocket between lower lid and eyeball. Gently close eyes. Place index finger over inner corner of eye for 1 min. Do not rinse or wipe the dropper or allow it to touch anything, including eye

Pearls

  1. Ciprofloxacin otic is not approved in children <1 y of age, not for ophthalmologic use, otic use only
  2. Intratympanic cipro product for use only during tympanostomy tube placement
  3. Available in otic formulation in combination with hydrocortisone (Cipro HC)
  4. Bacterial conjunctivitis is very contagious and spread by direct contact
97
Q

Counseling and Pearls - General Fluoroquinolones (otic, ophthalmic)

A

Counseling

  1. May warm solution in hands for 1 minute prior to administration
  2. Complete full course of therapy even if symptoms improve
  3. Otic: administer with affected ear upward, maintain position for at least 1 minute after instillation
  4. Ophthalmic: Wash hands with soap and water before/after use. Lie down or tilt head back. With index finger, pull down the lower lid of eye to form a pocket. Hold the dropper close to eye, but not touching, with the other hand. Drop the correct number of drops into the pocket between lower lid and eyeball. Gently close eyes. Place index finger over inner corner of eye for 1 min. Do not rinse or wipe the dropper or allow it to touch anything, including eye

Pearls

  1. Ciprofloxacin otic is not approved in children <1 y of age, not for ophthalmologic use, otic use only
  2. Intratympanic cipro product for use only during tympanostomy tube placement
  3. Available in otic formulation in combination with hydrocortisone (Cipro HC)
  4. Bacterial conjunctivitis is very contagious and spread by direct contact
98
Q

Counseling and Pearls - Nitrofurantoin

A

Counseling

  1. May make urine brown or red-tinged; this is not harmful and is a breakdown product of the drug
  2. Complete full course of therapy.
  3. For the suspension, shake well and store at room temperature, use within 30 days
  4. Avoid mixing suspension with food or beverages, but food can be taken afterward
  5. Symptoms should improve within 2-3 days; if they worsen, seek follow-up care

Pearls

  1. Nitrofurantoin does not reach effective levels in tissue and is only indicated for UTIs (not pyelonephritis)
  2. May resume normal activities after 24 h of antibiotics if afebrile
  3. Used to prevent recurrent UTIs but is also effective in the treatment of uncomplicated UTIs
99
Q

Counseling and Pearls - SMZ/TMP

A

Counseling

  1. Complete full course of therapy
  2. Symptoms should improve in 2-3 days; if they worsen, seek follow-up with health-care practitioner
  3. For suspension, shake well and store at room temperature and protect from light
  4. May cause photosensitivity; use sunscreen
  5. Maintain adequate hydration during therapy to prevent kidney complications
  6. Seek medical attention for severe diarrhea, dark urine, yellowing of skin or eye, unusual bruising or bleeding, blistering skin rash, or shortness of breath

Pearls

  1. Avoid use in patients with G6PD deficiency (increased risk of hemolytic anemia)
  2. Preferred agent forPneumocystispneumonia prevention in HIV-infected patients when CD4 count is <200
100
Q

Counseling and Pearls - Mupirocin

A

Counseling: instruct patient on proper application technique. Avoid drug exposure to open wounds, burns, or eyes

Pearls: the area treated may be covered with gauze dressing if desired

Top Drugs 1 (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions